EDSA Edesa Biotech, Inc.

Nasdaq edesabiotech.com


$ 1.75 $ -0.01 (-0.53 %)    

Friday, 31-Oct-2025 19:39:01 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 1.86
$ 1.90
$ 1.73 x 83
$ 1.88 x 75
$ 1.75 - $ 1.96
$ 1.55 - $ 4.49
210,894
na
13.09M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-Q
4 12-13-2024 09-30-2024 10-K
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 02-09-2024 12-31-2023 10-Q
8 12-15-2023 09-30-2023 10-K
9 08-09-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-10-2023 12-31-2022 10-Q
12 12-16-2022 09-30-2022 10-K
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-Q
16 12-28-2021 09-30-2021 10-K
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-Q
20 12-07-2020 09-30-2020 10-K
21 08-12-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-Q
24 08-14-2019 06-30-2019 10-Q
25 05-08-2019 03-31-2019 10-Q
26 02-05-2019 12-31-2018 10-Q
27 11-30-2018 09-30-2018 10-K
28 08-08-2018 06-30-2018 10-Q
29 05-07-2018 03-31-2018 10-Q
30 02-07-2018 12-31-2017 10-Q
31 12-01-2017 09-30-2017 10-K
32 08-09-2017 06-30-2017 10-Q
33 05-09-2017 03-31-2017 10-Q
34 02-06-2017 12-31-2016 10-Q
35 12-14-2016 09-30-2016 10-K
36 08-09-2016 06-30-2016 10-Q
37 05-09-2016 03-31-2016 10-Q
38 02-08-2016 12-31-2015 10-Q
39 12-14-2015 09-30-2015 10-K
40 08-10-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 edesa-biotech-results-from-phase-3-trial-of-paridiprubart-meets-primary-secondary-endpoints-with-statistical-significance-for-reduced-mortality-at-28-days

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics ...

 edesa-biotech-q3-eps-025-beats-029-estimate

Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29)...

 edesa-biotech-files-for-mixed-shelf-of-up-to-150m

-SEC Filing

 hc-wainwright--co-assumes-edesa-biotech-at-buy-announces-price-target-of-5

HC Wainwright & Co. analyst Yi Chen assumes Edesa Biotech (NASDAQ:EDSA) with a Buy rating and announces Price Target of $5.

 edesa-biotech-q2-eps-030-misses-029-estimate

Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.2...

 hc-wainwright--co-reiterates-buy-on-edesa-biotech-maintains-21-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Edesa Biotech (NASDAQ:EDSA) with a Buy and maintains $21 price ...

 edesa-biotech-fy-2024-gaap-eps-193-beats-215-estimate

Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(1.93) per share which beat the analyst consensus estimate of $(2.15)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION